|
U.S. Department
of Health and Human Services Introduction The issues of
substance abuse addiction and HIV transmission related to injection drug
use remain serious public health challenges, and the need to define and
implement effective public health interventions remain urgent. The
scientific research continues to define the unique role that syringe
exchange programs can play in curtailing the expansion of the HIV
epidemic in vulnerable communities affected by substance abuse, as part
of a well designed and implemented comprehensive HIV prevention
strategy. This paper
provides a review of recently published peer-reviewed research on
syringe exchange programs completed by senior scientists and public
health experts within the Department of Health and Human Services. An
overview of the research studies is followed by an annotated
bibliography providing the published abstracts, directly quoted, and
relevant commentary. In summary, the new studies contribute
substantially to the strength of the data showing the following effects
of effective syringe exchange programs: The data indicate that the presence of a
syringe exchange program does not increase the use of illegal drugs
among participants in syringe exchange programs, and in many cases, a
decrease in injection frequency has been observed among those attending
these programs. (Bold added) Throughout the
literature, the terms syringe exchange programs and needle exchange
programs have been used interchangeably in characterizing programs
providing sterile injection equipment to injection drug users. This
paper will use the term syringe exchange program, except where a
published abstract has specified needle exchange program. Overview Numerous studies
have shown that syringe exchange programs reach and serve the most
disenfranchised populations at high risk for HIV infection. In this
regard, syringe exchange -programs play a unique role in facilitating
the engagement of these populations in meaningful prevention
interventions and treatment opportunities, when implemented as part of a
comprehensive HIV prevention and substance abuse strategy. The
scientific evidence accumulated to date provides a basis on which
municipalities that are heavily affected by an HIV epidemic driven by
injection drug use should consider syringe exchange programs as a tool
for the identification, referral and retention of active users of
injection drugs into these services, as part of a comprehensive HIV
prevention plan. Serious
discussions about syringe exchange programs must be placed in the
context of the HIV epidemic in this country. The urgency to address the
consequences of substance abuse is clear, as injection drug use
continues to fuel the HIV epidemic in the United States. As many as half
of new HIV infections are caused by the sharing of injection equipment
contaminated with HIV, either directly due to injection drug use,
through unprotected sex with someone who acquired HIV infection through
injection drug use, or birth to a mother who acquired HIV infection
through these means (CDC, 1999). Women of color and their children
continue to be disproportionately affected by HIV/AIDS due to injection
drug use. An estimated three out of four AIDS cases among women are due
to injection drug use or heterosexual contact with someone infected with
HIV through injection drug use, and over 75% of new infections in
children result from the consequences of injection drug use in a parent
(CDC, 1999). All too often women are unaware of their risk, due to a
distant history of drug use in a partner. The ability to halt this
devastating epidemic, particularly among minority women and children,
requires a three part strategy: (I) preventing substance abuse; (ii)
facilitating entry of those with addictions into substance abuse
treatment; and (iii) establishing effective outreach to engage active
and former drug users in HIV prevention strategies that will protect
them, their partners and families from exposure to HIV, and bring them
into substance abuse treatment and medical care. HIV prevention and
treatment programs targeting HIV-infected injection drug users and their
partners, and similar programs within criminal justice institutions, are
also important components in preventing the transmission of HIV. In the
Department's prior reviews of the literature on syringe exchange
programs in 1997 and 1998, there was discussion of the methodological
issues and constraints present across most published studies in this
area. These include self-reported measures and difficulty in
establishing proper control groups. However, the Department's senior
scientists continue to concur with the conclusion of the Institute of
Medicine that the pattern of evidence is sufficiently strong to support
scientifically clear conclusions regarding the utility of syringe
exchange programs, in communities that choose to adopt them, as part of
a comprehensive HIV prevention strategy. A recent national
survey of syringe exchange programs (Paone et al,
1999) found that a
growing number of local communities have chosen to implement a syringe
exchange program to reach injecting drug users who are not in substance
abuse treatment, in order to reduce the transmission of HIV through
reduction in drug use behaviors and unsafe injection practices. This
survey also documented that, in addition to exchanging sterile syringes
for contaminated ones, 97% of syringe exchange programs provide a range
of other services including referral to substance abuse treatment,
prevention education for sexually transmitted diseases, HIV counseling
and testing, tuberculosis screening, and primary health care. These
trends also were found in a 1997 national survey (CDC,
1998). The biological
rationale for removing contaminated injection equipment from circulation
has been demonstrated in a new study by Abdala et al
(1999), confirming
empirical observations of previous studies. This study showed that HIV-1
can survive over 4 weeks in a contaminated syringe, remaining infectious
to individuals who reuse that syringe over this prolonged period. Riley
et al (1998) found that 10.9% of used syringes discarded in needle boxes
at community locations tested positive for the FUV antibody, while
Robles et al (1998) reported that 27% of contaminated syringes returned
to a new needle exchange program were positive for HIV. The longevity of
the HIV-I virus, combined with its prevalence in used equipment in some
communities, is basic to the public health rationale for removal of used
syringes from the community environment. Knowledge of the
effectiveness of syringe exchange programs in reducing the sharing of
injection equipment and reuse of contaminated syringes among injection
drug users has recently been reinforced by a number of new studies (Heimer
et al, 1998; Robles et al, 1998;
Bluthenthal et al, 1998). Conversely,
the closing of an established syringe exchange program in Connecticut
was associated with an increase in reuse and sharing of contaminated
equipment among injection drug users, exposing these individuals and
their partners and families to an increased risk of preventable
bloodborne diseases (Broadhead et al, 1999). Recent research
studies document the role that effective syringe exchange programs serve
as mechanisms to engage very high risk and hard to reach individuals in
substance abuse treatment services. Brooner et al (1998) found that half
of syringe exchange program clients referred for substance abuse
treatment actually entered treatment, with 76% completing the first 13
weeks of treatment. These results were achieved despite the fact that
these clients had more severe drug use, more HIV risk behaviors, less
employment and greater engagement in illegal activities than, clients
referred to substance abuse treatment from traditional sources. Hagan et
al (In Press) reported reduced frequency of injection drug use among
current and former users of a needle exchange program, and entry into
methadone treatment programs among former, current and new users of a
syringe exchange program. Strathdee et al showed that attendance at a
syringe exchange program was positively associated with individuals
entering detoxification services independent of other variables, again
representing an important bridge that facilitates entry into substance
abuse treatment. Concerns about elevated HIV seroconversion rates linked to the use of syringe exchange programs remain scientifically unfounded, as the data primarily reflect the impact of multiple high-risk factors among individuals who participate in these programs - a population at extremely high risk that. is not engaged in appropriate interventions through traditional mechanisms of outreach and treatment referral. Studies of HIV incidence among two study cohorts in Canada, and some recent data on the incidence of hepatitis B and hepatitis C in Seattle, are relevant as these relate to syringe exchange programs. In the Department's internal review of these data in 1998, careful attention was given to the study data on these Canadian cohorts, with the conclusion that syringe exchange programs were not associated with an increase in HIV seroconversions: Subsequent data from the Montreal cohort (Bruneau et al, 1999) have confirmed this lack of association between HIV seroconversion and attendance at a syringe exchange program, with longer follow-up of the study participants and appropriate availability of sterile injection supplies. Efforts to identify any grounds for a causal relationship continue to show negative results (Schecter et al, 1999), when controlling for risk factors in the statistical model. Public health scientists have long known about the incidence of hepatitis B (HBV) and hepatitis C (HCV) among injection drug users. These are highly infectious bloodborne diseases that are endemic among some drug-using populations. In Seattle, where there is a high prevalence of hepatitis C among injection drug users (70%-80%), participation in the syringe exchange program did not appear to be protective against new HCV or HBV infection (Hagan et al, 1999). Because of the high background prevalence of HCV in this population, a single exposure to a syringe used by an injection drug user carries a high level of risk that it will be contaminated with HCV. Although syringe exchange programs can greatly reduce the reuse of contaminated syringes, maximal prevention of HCV transmission among this population would require distribution of a sufficient volume of sterile syringes to preclude any reuse of injecting equipment. In contrast to this scenario, since HIV seroprevalence is yet low in this population, the empirical data support the potential of a protective effect for HIV among individuals seeking clean injection equipment at the syringe exchange program. In summary, injection drug use is a driving force for new HIV infections, disproportionately affecting minority populations. Yet, HIV transmission via injection drug use is preventable. Efforts to halt the HIV epidemic are in part dependent on effective prevention interventions targeted to this population. Prevention will require successfully engaging injection drug users and bringing them into systems of care that offer substance abuse treatment, mental health, medical, and social support services. The availability of medical, social and preventive services alone are often not enough to engage the highest risk populations of active injection drug users, absent effective methods of outreach to this population. The scientific research has shown that well designed and implemented syringe exchange programs have demonstrated efficacy in engaging populations at severe risk for HIV and reducing the further spread of HIV among injection drug users, their sexual partners and children. Furthermore, these programs have not been shown to encourage the use of illegal drugs, and fit well into comprehensive substance abuse treatment strategies. After reviewing all of the research to date, the senior scientists of the Department and I have unanimously agreed that there is conclusive scientific evidence that syringe exchange programs, as part of a comprehensive HIV prevention strategy, are an effective public health intervention that reduces the transmission of HIV and does not encourage the use of illegal drugs. In many cases, a decrease in injection frequency has been observed among those attending these programs. In addition, when properly structured, syringe exchange programs provide a unique opportunity for communities to reach out to the active drug injecting population and provide for the referral and retention of individuals in local substance abuse treatment and counseling programs and other important health services. The scientific evidence accumulated to date provides a basis on which municipalities that are heavily affected by an HIV epidemic driven by injection drug use should consider syringe exchange programs as a tool for the identification, referral and retention of active users of injection drugs into these services, as part of a comprehensive HIV prevention plan. Highlights of this review Statement from Congresswoman Nancy Pelosi releasing the Surgeon General's review, April 13, 2000. Letter from Secretary of Health and Human Services Donna E. Shalala submitting the Surgeon General's review to Congresswoman Nancy Pelosi.
|